CompletedPhase 4

Language-based Learning Skills and Attention Deficit Hyperactivity Disorder (ADHD): Impact of Treatment With Sustained-release Guanfacine

United States30 participantsStarted 2010-06

Plain-language summary

This study is investigating the effect of sustained-release guanfacine (Intuniv) on language-based learning skills in children age 6-12 who are diagnosed with attention deficit hyperactivity disorder (ADHD).

Who can participate

Age range6 Years – 12 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Diagnosis of ADHD-inattentive or combined type. Exclusion Criteria: * Intelligence (IQ) below 85 as determined by formal testing. * Identified or suspected genetic syndromes. * Autism or other pervasive developmental disorders. * Psychiatric disorders other than ADHD and oppositional defiant disorder. * Heart, liver or renal disease. * Cancer. * Epilepsy or non-febrile seizure history. * Cardiac arrhythmia, bradycardia, or syncope. * Any other condition considered to be potentially exacerbated or endangered by treatment with an alpha-2 agonist drug.

What they're measuring

one-tailed t-test

Timeframe: 7 weeks

Trial details

NCT IDNCT01146002

SponsorNeurology Group of Bergen County, P.A.

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2013-02

View on ClinicalTrials.gov More Attention-deficit/Hyperactivity Disorder trials